Article

Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change

T. Fulop [1]*, A. Larbi [2], G. Pawelec [3], A. A. Cohen [4], G. Provost [4], A. Khalil [1], G. Lacombe [1], S. Rodrigues [5,6]*, M. Desroches [7,8], K. Hirokawa [9], C. Franceschi [10] and JM Witkowski [11]

[1] Research Center on Aging, Geriatric Division, Department of Medicine, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Québec, Canada

[2] Singapore Immunology Network (SIgN), Agency for Science Technology and Research (A*STAR), Immunos Building, Biopolis, Singapore, Singapore

[3] Department of Immunology, University of Tübingen, Tübingen, Germany; Health Sciences North Research Institute, Sudbury, ON, Canada

[4] Groupe de recherche PRIMUS, Department of Family Medicine, University of Sherbrooke, 3001 12e Ave N, Sherbrooke, QC, J1H 5N4, Canada

[5] Ikerbasque, The Basque Foundation for Science, Bilbao, Spain

[6] BCAM - The Basque Center for Applied Mathematics, Bilbao, Spain

[7] MathNeuro Team, Inria Sophia Antipolis Méditerranée, France

[8] Université Côte d'Azur, Nice, France

[9] Institute of Health and Life Science, Tokyo Med. Dent. University, Tokyo and Nito-memory Nakanosogo Hospital, Department of Pathology, Tokyo, Japan

[10] Alma Mater Studiorum University of Bologna, Italy; Laboratory of Systems Biology of Healthy Aging, Department of Applied Mathematics, Lobachevsky State University, Nizhny Novgorod, Russia

[11] Department of Pathophysiology, Medical University of Gdansk, Gdansk, Poland

* Correspondence: Tamas.Fulop@Usherbrooke.ca (T.F.); srodrigues@bcamath.org (S.R.)

Abstract: Organismal aging is associated with many physiological changes including differences in the immune system of most animals. These differences are often considered to be a key cause of age-associated diseases as well as decreased vaccine responses in humans. The most often cited vaccine failure is seasonal influenza, but while it is usually the case that the efficiency of this vaccine is lower in older than younger adults, this is not always true and the reasons for differential responses are manifold. Undoubtedly, changes in the innate and adaptive immune response with aging are associated with failure to respond to the influenza vaccine, but the cause is unclear. Moreover, recent advances in vaccine formulations and adjuvants as well as in our understanding in immune changes with aging have contributed to the development of vaccines such as those against herpes zoster and SARS-CoV-2 which can protect against serious disease in older adults just as well as in younger people. In the present article, we discuss the reasons why it is a myth that vaccines inevitably protect less well in older individuals, and that vaccines represent one of the most powerful means to protect the health and ensure the quality of life of older adults.

Keywords: immunosenescence; inflammaging; vaccination; influenza vaccine; pneumococcal vaccine; herpes-zoster vaccine; COVID19 vaccine; immunobiography; trained immunity; adaptive complex systems; mathematical model; tipping point

1. Introduction

Vaccination is one the greatest achievements of humankind and probably the single greatest success of modern medicine [1]. Vaccination has dramatically reduced child mortality from most of the common infectious diseases. The vaccination programme for children is extremely well organized and effective. On the other end of the spectrum of life, namely in older adults, the necessity for vaccination became of interest for many scientists [2-4]. Still there is a common thinking that immunosenescence leads to a degree of

immunodeficiency which directly decreases vaccine immunogenicity as well as efficiency for all older subjects [5,6]. This opinion can be found in essentially every article and textbook treating of age-related changes in the immune response and their consequences [2-6]. Furthermore, the alteration of the immune response is seen as responsible for not only vaccine failure in older subjects but also for increased vulnerability to natural infections, an idea that gained even more support during the present COVID19 pandemic due its disproportionate impact on older subjects [7-10]. However, it should be stressed that underlying co-factors associated with aging such as co-morbidity, genetic and environmental factors, and overwhelming inflammaging may play a more determinant role in COVID susceptibility than age *per se* [11].

It should be recognised that there are increasingly many vaccines proposed specifically for older subjects. However, at the beginning the most used were the influenza and pneumococcal vaccines, which were indeed often less effective in older subjects, but were not so efficient in the younger subjects either [12-14]. This decreased immunological efficacy was related to the changes of the immune system with aging presently conceptualized under the concept of immunosenescence and inflammaging [15-18]. It cannot be denied by any means that immune changes occur with aging; however, these changes cannot be treated as a monolithic block because time does not have the same effect for all humans, due in large part to the heterogeneity of immunobiography [19,20]. This nuanced view of aging is increasingly accepted and widespread and should direct our appreciation of vaccine efficacy in older adults [21,22].

Nevertheless, with our increased understanding of how the immune system responds to vaccines and of how the immune system changes with aging, it became evident that the problem was partly related to the vaccines themselves and not to the older subjects' immune response. No interventions can be expected to be 100% effective either in young or in older subjects. In this article we will discuss the immune system requirements for an effective vaccine response, the immune changes related to this vaccine response during aging, the development of new vaccines and their usefulness in older adults.

2. The Immune Response assuring an Effective Vaccine Response

Since the introduction of the first form of vaccination in the West by Jenner there is an enormous effort to unravel what should be the most efficient immune response for a successful vaccine response [23]. The ultimate aim of vaccination is to create a surrogate of natural infection by inducing long-lasting immune memory through coordinated, complex immunological interactions [24]. This outcome is fundamental for the protection of the organism when it again encounters the actual infectious agents. First, we briefly review the physiological immune response to vaccines, before describing the changes underlying putative vaccine failure in aging.

The antigen under any form which is injected to the organism first encounters the innate immune system or is carried out directly to the lymph nodes, where coordinated reaction of innate and adaptive immunity occurs [25,26]. The antigen presenting cells (APCs), mainly dendritic cells (DC) and macrophages engulf the antigen, process it to short peptides and present it via the major histocompatibility complex (MHC) to T cells [27,28]. Adequate functioning of the innate immune system is extremely important not only for antigen presentation but also for the productionof various cytokines which will guide the activation of adaptive immunity and the differentiation of the different T cells [29,30]..

In the adaptive arm in reaction to antigens the CD4[+] T cell priming is the key event for vaccine immunogenicity, resulting in specific antibody production by B lymphocytes and plasma cells and generation of long-lasting immune memory T cells [31]. This priming is highly modulated by various factors such as the local pro-inflammatory environment, vaccine formulation and the nature of the vaccine [32,33Antigens stimulate the CD4[+] T cells depending on the cytokine milieu modulated by APC-secreted IL-12 to become either effectors or helpers for CD8[+] cytotoxic effector T cells by the action of IL-2,

IFNγ, TNFα or by the APC-secreted IL-10 to differentiate into Th2 and those activating B cells [34,35]. As a consequence, all of them begin to proliferate intensively [36-38]. The CD8[+] T cells may also be directly stimulated by antigens in the context of MHC-I to become effector T cells. The B cells become plasma cells by the coordinated action of the follicular dendritic and CD4[+] T cells and undergo different changes for producing the highly specialized neutralizing antibodies against the antigen [39,40]. In the meantime, the clones of primed T cells that became differentiated specific effector cells will slowly shrink and ultimately die, leaving highly effective memory cells to combat future identical specific infections [36,41]. All this complex interactive priming necessitates coordination, functionality, a large enough number of cells, functional receptors, coordinated intracellular signalling, and finally a solid immune memory.

This optimal immune activation chain of events which occurs the most frequently in young individuals often decreases around age 60. However, age-related immune changes occurring at any level of this coordinated action and developing through decades were considered as detrimental and being the main reason for vaccine failure with aging.

3. What are the Changes which are Commonly considered to Alter the Vaccine Response with Aging?

Aging is not a uniform process; rather, it consists of various processes on the road of aging [42]. This means that older subjects may age successfully with few alterations, normally with compensated changes, or pathologically with many changes in their immune functions [43-47]. The relatively new distinction of biological aging from chronological aging is also changing our understanding of aging as it became a time-scale related process where the same passage of time does not imply the same biological changes for all individuals, in accordance with the immunobiography and with the adapt-immune concept of aging [20,48]. This is even more evident if we consider the recent appreciation of frailty as a measure of the biological age [49]. Furthermore, the new approach via systems biology or the complex systems concept showed that the immune system cannot be considered cell by cell, cytokine by cytokine, but only as a whole complex ever-adapting system [50-53]. A complex systems view is necessary to capture the unique aspects of the vaccine response of younger versus older immune systems [54]. Finally, the introduction of multi-omics approaches to capture the multilayer components and complexity of the immune response either in populations of cells or at the single cell level opened new ways to assess the immune response to vaccines. Very recently our comprehension of the aging immune response benefitted largely from these advances either for the understanding of what is occurring in the human immune system under natural infections or under vaccine administration as well as for the conceptualization of new vaccines [55].

What changes have been described to affect the immune response to vaccines in older subjects? Collectively, age-related immune changes are described as immunosenescence and inflammaging. Changes that could impact vaccination in the innate immune system are numerous [56-61]. The most important one is the generation of a low-grade inflammation, mainly by the activation of the macrophages (i.e. inflammaging) [62]. This creates an environment which is detrimental for the generation of an adequate immune response to vaccine. This increase is partially due to the constitutive stimulation of the PRRs to produce pro-inflammatory cytokines, which renders them less effective at responding to specific stimulations [63-65]. Another potentially noxious event is the alteration in the antigen presentation, mainly by the DCs [66]. With aging these cells are unable to efficiently process and present the antigens to the T cells; additionally, the production of cytokines is not suitable to the priming of the adaptive immune response [67-69]. The changes observed in the lymph nodes with aging also contribute to the altered vaccine response [25,70].

However, once the APCs are able to prime the adaptive immune response, the cells composing this arm may also be different in older individuals [71]. There are phenotypic and functional alterations. The most important phenotypic alteration is the decrease in

naïve cell numbers, mainly in the CD8+ T cell subpopulation, thereby precluding the priming by new antigens [72]. This is most commonly related to the thymic involution [72-78]. Even if the relevant cognate T cells have been found in aging individuals, their T cell receptors (TCR) present a decrease in the signaling efficiency either because of the membrane changes with aging in the cholesterol content or because of the alteration in signal transduction, resulting in less efficient transmission of the signal from the surface to the nucleus [79-82]. There are also alterations in the effector functions of the T cells, which are decreased and lead to difficulties in eliminating invading pathogens. Once the infection is resolved, memory should develop, but with aging instead some effector T cells will survive, becoming either senescent or exhausted [83,84]. It seems then that instead of becoming true memory cells they may somehow maintain innate and effector functions, which may be somehow an adaptive process for a better immune response [83,85-90]. Most of the studies indicate that the highly differentiated T cells, mainly CD8+ T cells, become senescent or even acquire senescence-associated secretory phenotype (SASP) [91,92]. However, the discussion is ongoing for years whether all these cells are senescent or exhausted. Many results seem to suggest that they are also functionally exhausted, which further impairs the vaccine response [93,94]. We should nevertheless stress that the phenotypic and functional T cell subsets develop from naïve cells to memory cells through a dynamic process with underlying distinct molecular mechanisms as well as different distributions throughout the body [92,95,96]. Together, the changes observed in the cellular immune response with aging may impact the vaccine response of the older subjects by decreasing clonal diversity due to the decrease in naïve T cells, contraction of the TCR repertoire and the difficulties to generate long-lasting immune memory [97]. However, as our understanding, experimental skill, and technical ingenuity are increasing, the one-way appreciation of these changes is being toned down and a more nuanced picture is appearing, favouring the building of vaccine interventions and development on the existing adaptive processes of the aging immune system [48, 98-101].

The other partner of the adaptive immune response, the B cells, is also considered as altered with aging [102,103]. The number, the phenotype and the functioning of the B cells change with age [104]. The switch into specific neutralizing antibodies by somatic hypermutation is changed decreasing the ability of these antibodies to neutralize pathogens with aging [105]. The development of efficient B memory cells is also deficient. These alterations in efficient antibody production are due to intrinsic as well as to extrinsic (e.g. T cell) changes with aging. All these described changes in the adaptive immune response adversely alter the vaccine response [106-109].

The molecular underlying causes of these alterations have also been somewhat elucidated in recent years [110]. One of the most important changes are in the epigenome [111-113]. This closely modulates the transcription and the accessibility to the chromatin. The epigenetic changes are different in CD4+ and CD8+ T cell subpopulations, which may underlie the higher susceptibility of naïve CD8+ T cells compared to the naïve CD4+ T cells [114-116]. The successive differentiations induce telomere shortening contributing but are not sufficient to induce cell senescence [87, 117,118]. The overproduction of free radicals resulting from the changes in mitochondrial functions with age induces genomic instability, leading also to T cell senescence [119-121]. Finally, the various changes in the surface receptors induce changes in signal transduction, decreasing the efficacy of T cell activation [122-125]. Some miRNAs alterations with aging in T cells may also influence the functionality as well as the differentiation of T cells [126,127].

The corollary or the other side of immunosenescence is inflammaging as first defined by C. Franceschi [17]. Because of the intrinsic and extrinsic challenges, the innate part of the immune system produces significantly increased pro-inflammatory mediators which are not compensated by anti-inflammatory mediators [128]. This concept of macrophage-centered inflammaging has been greatly extended in recent years, with over-activation of the adaptive immune system, senescent cells (SASP), the microbiome, and mitochondrial dysfunction being identified as contributing factors. Thus, inflammaging is suggested to be the major underlying cause for the age-related chronic diseases such as

cardiovascular disease, cancer, and neurodegenerative diseases [62,99,129,130]. Furthermore, it is also well established that over-inflammation in the aging organism decreases vaccine efficacy either locally or systematically [131,132]. Therefore, modulation of immunosenescence and inflammaging may be a target for increased vaccine efficacy in older adults [133].

4. New Evidence from Experimental Data on Vaccine Response in Old Age

One of the most important breaches in the generalized consideration of age-related immune changes as deleterious came from recent studies showing that perhaps the decrease in naïve cells due to thymic involution is not as dramatic as was assumed from murine studies. More generally, many recent studies in humans contradict longstanding concepts established from rodents research. Thus, it seems that the TCR diversity due to the low thymus activity, may be compensated by the homeostatic proliferation and the stemness of some memory T cells potentially fulfilling the lifetime necessity for new TCRs during new infections [134-139]. However, very recent data indicate that the pool of naive CD8 + T cells contracts with ageing due to reduced thymic production, while the pool of naive CD4 + T cells is maintained to some extent through robust homeostatic proliferation [140]. Though this is still being debated, substantial progresses have been made to better asses the clonal diversity of T cells [139]. This also agrees with the observation from clinical practice that older patients are doing much better than we could suppose considering the experimental studies. While COVID-19 is often portrayed as an example of the impacts of immune aging, it is actually an example of the opposite: successfully aging older adults recovered easily from this new infection, and high susceptibility appears to be more linked to comorbidities and cumulative impacts of unhealthy lifestyles than of age itself [140]. This is confirmed by the observation that there was almost no COVID mortality in any age group in the non-industrialized Tsimane horticulturalist population, despite high infections rates (Michael Gurven, personal communication). Of course, the co-morbid frail individuals suffer serious and deadly illness from the SARS-CoV2 [141,142].

Moreover, while the number of naïve T cells may be sufficient to sustain the vaccination effects even with a new antigen, it could be that defects in the innate immune system may hamper the effective immune response to the vaccine. However, recent experimental data supporting the notion that inflammaging may be an adaptive process in conjunction with what is called "trained innate immunity" highlights the possibility that the innate immune system could effectively prime the adaptive immune response also in older individuals [79,146,147]. These new discoveries suggest that a better cooperation among the innate and adaptive immune response is possible in older subjects.

Recent discoveries suggest that new T cell subpopulations may exist in older subjects, namely T cells with more effector capacities, which may favor the development of better memory when the challenge is eliminated [76,87]. The new data coming from multi-omics studies concerning senescent T cells also indicate that some of them are only exhausted, which leaves the possibility to reactivate them via blockade of checkpoint inhibitors. Furthermore, these senescent cells may retain some important effector functions, which in turn could be important for memory acquisition after the elimination of the pathogen [133].

What are we to make of these new findings after so many decades of research that seemed to show reduced immune functionality with age, consistent with ideas of reduced vaccine efficacy in older adults? Several concepts from complex systems theory provide plausible explanations. Most broadly, many complex biological systems show degeneracy, which is the potential to arrive at a functionally equivalent result via alternative mechanisms [144]. The best-known (but trivial) example is the degeneracy of the genetic code, with multiple codons potentially specifying the same amino acid. More relevant here, about 30% of genes, including albumin, produce no apparent change in phenotype when knocked out completely. This startling finding arises because the architecture of the underlying regulatory networks has been selected for robustness and can thus ensure

basic functioning of the system. It is likely that the aging immune system has numerous aspects of degeneracy, which allow it to arrive at similar (emergent) functional capabilities under a wide array of immunobiography. In fact, such degeneracy would seem absolutely necessary to maintain a functional immune system across the life course despite the incredible heterogeneity of individual immunobiography as reflected even in the cross-reactivity of TCR [145,146].

Degeneracy might manifest in three specific ways during immune aging. First, there are many aspects of immune aging that are likely adaptive. Historically, the largest risk of encountering new pathogens would mostly have been at younger ages, with some degree of saturation of memory. Counter-balanced with the risk of cancer and autoimmune disease, a reorganization of the immune system might have been actively selected for in later life. In this context, differences between young and old immune systems might be more like differences between male and female immune systems: arriving at largely similar endpoints via different pathways, and with some specific differences related to the differing needs of the groups, and with some specific vulnerabilities due to the inherent trade-offs in the system [147].

Second, some immune changes with age may be pathological. Such pathological changes are likely to be diverse, depending on an individual's immunobiography. Degeneracy may be a buffering mechanism permitting the system to persist with relatively similar overall functionality despite deficits in certain components. Generally, in highly optimized complex systems, such buffering creates a dynamic of apparently stable systems that show a rapid or abrupt decline when their capacity is exceeded, reflecting the trade-offs needed to maintain function under the most common conditions, at the expense of continual buffering capacity when tolerance is exceeded [148,149].

Third, degeneracy could reflect the ability of the system to arrive at relatively similar functional outcomes through progressively less desirable pathways. There may be ways in which the younger immune system achieves its objectives slightly better than the older immune system, such that as the immune system ages it invokes numerous compensatory mechanisms for deficits that arise (either in specific individuals, or generally during aging), but these compensatory mechanisms are partial, permitting the system to continue but as some cost. For example, responses to certain types of pathogens might be lower, energetic efficiency of the system might be compromised, or secondary effects, such as consequences of cellular senescence, might be induced [150,151].

Of course, beyond degeneracy and complex systems, some aspects of the aging immune system may also be functionally superior – most obviously, the accumulation of immunity to a greater and greater range of pathogens with age provides superior protection even if could not be the case for all of them. It is likely that all four of these processes (three aspects of degeneracy discussed above and the adaptive aspects of aging) coexist, and the changes we observe in the immune system with age are a mix which we are not yet able to distinguish well. This would explain why clear decrements in many individual immune components are observed, but without a clear decrement to overall function, with major differences across individuals, and with some net generalized functional gains (e.g. increased per-cell cancer resistance) and losses (e.g. decreased influenza vaccine response) [152]. It is also consistent with continued vaccine efficacy in older adults, but with, in some cases, the need for specific formulations that work better in aging immune systems.

5. How does the Aging Immune System Respond to Various Existing Vaccines and how the vaccine modifications improve the response?

There are several vaccinations which are recommended for older subjects all around the world [153]. These include the influenza, pneumococcal, zoster and tetanus vaccines, as the infections in question are causing either serious illnesses or being even deadly in older subjects. The vaccine type recommendation, age, and mode of administration may change across countries.

The most studied vaccine is the influenza one [152,154,155]. The myth that vaccines are not efficient for the elderly population come from the lack of success of this vaccination. Indeed, the immunogenicity and efficiency of the standard dose influenza vaccine is about 20-50% in older adults vs 60-90% in younger adults, however depending on the season and the population [156]. The efficiency even in young people is not 100%. The standard dose influenza vaccine contains three or four antigens from the previous influenza season produced in chicken eggs or now in insect cell cultures. This standard vaccine is administered intramuscularly and contains 15μg of each antigen. It is known not to be able to elicit efficient memory T cell response [157-159]. The production of specific haemagglutinin inhibition (HI) antibodies is also decreased [160-162]. These data prompted the contention that older adults do not respond to vaccines in general. However, the type of vaccine, the route of administration and the quantity were simply not adjusted for the aging-modified immune systems of elderly. Since as these characteristics have become known, the vaccine composition has been changed. The vaccines (Fluzone High-Dose®, Flublok®) contain high doses (45 or 60μg, i.e. three or four times the standar dose) of hemagglutinin A (HA) antigen from each of the included strains of the virus [163], become tetravalent and in some cases are conjugated with a new adjuvant, M59 (e.g. Fluad®) [164-167]. There is substantial improvement in the protection of older individuals with the high dose vaccines [163]. The adjuvanted ones were not tested directly against the high dose vaccines, but they are significantly more efficient than the standard dose vaccines. The alternate route of subcutaneous injection was also tested and subsequently abandoned [168]. The measure of the efficiency of the influenza vaccine is also questionable as only an increase in the antibody titer more of than 1:40 was considered as protective, resulting in at least a 50% protection rate. The cellular immunity, notably the functionality of the CD8+ T cells was not tested or did not show real impact on functional T cell memory [169]. Together the new vaccines against influenza are much more effective than the first generation of vaccines by inducing a strong humoral and memory T cell response [152,170-172]. Therefore, either the adjuvanted inactivated trivalent vaccine or the quadrivalent cell-cultured inactivated vaccine or the high-dose tri- and tetravalent vaccines are recommended for older subjects as efficient.

The next vaccine recommended for older subjects is the vaccine against *Streptococcus pneumoniae*. The most used is the 23-valent pneumococcal polysaccharide vaccine (PPSV23) which contains the 23 most important infectious serotypes. This vaccine is highly inefficient in the elderly either in terms of antibody production or in terms of the protection against community acquired pneumonia (CAP). It can have some efficacy against the invasive pneumococcal disease (IPD) [173-177]. The new conjugated vaccine, which is now the most frequent in older subjects, is the pneumococcal conjugate vaccine (PCV13) which contains only 13 serotypes, and it is very efficient in older adults [178]; however, it may leave a place for serotype replacement [179]. The efficiency of this conjugated vaccine is very high in the older population as demonstrated by many studies, e.g., CAPiTA [180,181]. This vaccine is able to induce protective antibody production and memory of adaptive immune cells [182,183]. It is able to reduce occurrence of CAP in an elderly population by 74%. This vaccine is already recommended in the USA and has replaced the PPV23 alone. In the development pipeline the PCV20 is called to replace the PCV13 mainly in the elderly to combat the serotype replacement threat [184,185]. The clinical trials of the latter vaccine are very promising in older subjects. This will probably supplant all other anti-pneumococcal vaccines in older subjects to increase their protection

against this deadly pneumonia. Vaccination of children underperformed expectations, necessitating maintenance of strong vaccination in older adults [186].

One of the biggest successes of vaccination in older adults and a clear demonstration that vaccines can be highly efficient in this population is the adjuvanted anti-herpes zoster vaccine. The first vaccine, the Zostavax, was an attenuated virus vaccine whose efficacy waned over time because of a decrease in T cell immunity [187,188]. However, the second generation adjuvanted anti-herpes zoster vaccine, SHINGRIX, demonstrated an excellent efficacy for both its immunogenicity and its clinical efficacy [189]. Even the long-term protection has been revealed remarkable as it lasts already for 9 years [190,191]. The vaccine is composed of 2 components, a real viral but recombinant antigen, gE, involved in viral replication, and the adjuvant, AS01B, acting on the innate immune response via TLR [192,193]. The adjuvant AS01B consists of 3-O-desacyl-4'-monophosporyl (MPL) lipid A and QS-21. The efficacy of this vaccine clearly demonstrated that if we know what the changes in the immune system are with aging, we are able to design sufficiently efficient vaccines to overcome the changes. This also demonstrates that a vaccine should be complex-system-oriented and not targeting only one aspect of the immune response.

The other very recent vaccination success story is the unexpected efficacy of the COVID-19 vaccine in older adults [194-197]. However, the data recently published seem to indicate that age could be an important factor to explain the decrease in SARS-CoV-2 anti-S IgG after vaccination with two deses of BNT162b2 vaccine [202,203]; however, others indicate that even if this was less in older subjects the level of antibodies was well above what is considered protective [204]. The most recent reports are demonstrating that older subjects are responding as efficiently to the mRNA vaccine as young subjects after the third dose [205,206]. This was perceived as unexpected; however, in light of success of SHINGRIX it should have been expected, as the mRNA apart from being the instruction for making the virus antigen act also as an adjuvant preparing a coordinated immune response even if SARS-CoV-2 spike antigens were neoantigens [198-200]. Indeed, the lipid emulsion protecting the mRNA from destruction as well as the mRNA itself are considered as solid adjuvants. Considering this, it seems that their use is stimulating a favourable innate immune milieu which will be able to efficiently stimulate the adaptive immune response.

6. Perspective on Mathematical Modelling, Illustrating the Role of Immunobiography in Vaccine Efficiency

To give a glimpse on what could be achieved by mathematically modelling of the immune history as a complex adaptive system for demonstrating the various paths for adaptation/maladaptation which may lead to an efficient response to vaccines, we focus for simplicity on one feature of a complex system, namely that of multiscale property [217]. Specifically, we consider the multiple timescale feature and assume that the immune history can be described by just two immunobiographical variables (more variables could be considered) and that these evolve on different time scales. We show that such systems are sensitive to small perturbations and these perturbations trigger the entry towards an emergent *tipping point* that causes differential ageing of the immune system by either precipitating or delaying the transition to "immune exhaustion" (where the immune system is less efficient in its response, but with the correct clinical intervention the system can reactivate). To guide the reader, we substantiate these ideas with **figure 1**. In panel A, we depict two immunobiographical variables (I_1 and I_2) that dynamically interact and generate the time-dependent energy landscape (represented by the green surface) where the immune history evolves nonlinearly in time. The laws that govern this interaction can in principle be described by a multi-timescale differential equation (as shown), where each of the immunobiographical variables evolves according to its own natural characteristic time (here I_1 evolves with slow time-scale εt and I_2 evolves with chronological time-scale t). Noteworthy, each of the immunobiographical variables can be seen as an order parameter, which can be thought of as a "name" that represents several components with either

pairwise or higher-order (possibly time-varying) interactions (see panel B). In the latter case, such higher-order interactions form so-called simplicial complexes [218]. These immunobiographical variables are organised in different layers (i.e. a multi-layered network or simplicial complex) each characterised by a different time-scale. In panel C, we write down a specific example of a multiple-timescale differential equation (for immunobiographical variable I_1 evolving with slow-time scale and I_2 evolving fast), which could describe a possible scenario of the immune history within its time-dependent energy landscape. To succinctly and geometrically interpret its time history, we plot its evolution in *phase plane*, that is, a space in which variables from different layers (of the network or simplicial complex) interact (see panel B) and where one can identify all possible emergent states resulting from the interaction between the immunobiographical variables (in this case I_1 and I_2). In this example, the interaction between I_1 and I_2 give rise to two emergent states, namely, a *tipping point T* and the end state *"immune exhaustion"*. Specifically, the competition of time-scales between I_1 and I_2 creates regions of phase-space geometrically akin to a bow-tie funnel structure with both contracting and expanding directions and in the centre of it there is a tipping point (see panel E). This funnel structure attracts trajectories (i.e., acts as a magnet forcing the immune system history towards it); subsequently the tipping point induces time-delays and finally it expels the trajectories into different directions of the phase plane. However, the induced time-delays and subsequent ejections into different directions of phase plane are determined by the amount of initial small perturbation (e.g., pathologies, accidents, diet, life style, etc.) to the immune system (see panel C and E). In effect small perturbations trigger the entry towards an emergent "magnet" funnel structure with a tipping point that causes differential ageing of the immune system. The immune system inevitably reaches an end-point, "immune exhaustion", but the uncertainty lies in the time that the immune system takes to reach "immune exhaustion", which is determined by small perturbations and multiple-timescale interactions between the immunobiographical variables (see panel C, where three immune history examples triggered by different perturbations lead to three different history outcomes, that is with different delays τ_1, τ_2, τ_2). The evolution of these three immune history examples is also provided in Panel D1 and D2 where we depict (in chronological time) the history of I_1 and I_2 respectively (Figure 1).

Figure 1. Mathematical modelling the immune history, critical transitions towards differential ageing. Panel A: Time varying energy landscape (green) induced by the interaction between immunobiographical variables with different timescales, which is given by the differential equations; the functions f and g describe the evolution law of the immunobiographical variables as well as their interactions. Finally, ε is a small parameter. The immune history evolves on this landscape (see black trajectory segment). **Panel B:** The immune system as an adaptive complex multiscale system, where each layer (scale) is a network or simplicial complex of interacting components. Each layer can be summarised by an order parameter I_i. **Panel C:** A specific model example of a 2-dimensional multiscale immune system; the function h can for instance be a quadratic polynomial, and ε and α are parameters. The different immune history is shown in phase-plane, where different perturbations leads to different immune history (trajectories) outcome that reach "immune exhaustion" with different time delays (i.e. τ_1, τ_2, τ_3). Note that different immune history can be associated with different individuals or with the same individual receiving different perturbations. Panel D1 and D2, depict

the corresponding trajectories of I_1 and I_2 in chronological time. **Panel E:** A zoom of the lower part of figure C. The competition of timescales between I_1 and I_2 create a funnel structure and a tipping point. Trajectories first contract onto the funnel and initially their biological age is not affected, however, past the tipping point T, different biological age is induced (i.e. τ_1,τ_2,τ_3) which is dependent to small perturbations. **Panel F:** Chronological time is linear while biological time is nonlinear with many components inducing either slow or fast timescales, depending on the individuals and the various perturbations that they will suffer across life indicating differential adaptations of the immune system during aging underlying the differential vaccine response.

To summarise, competition of timescales between immunobiographical variables leads to an immune system that is sensitive to perturbations (or initial conditions) without being chaotic and where several aging history scenarios compete. The dominant history outcome is in fact decided by a small perturbation. That is, different perturbations lead to differential aging (or differential immune history), where each aging scenario has a different delay and, consequently, reach "immune exhaustion" at different (chronological) times. Panel F summarises the concept by showing that chronological time is linear while biological time is nonlinear due to its many components with several timescales that compete and the various perturbations that an individual suffers across life determines the immune history and age. Therefore, the efficiency of the vaccine in older subjects does not depend on the chronological age as always stated but ultimately from the use of appropriate vaccines built on the immunobiographical adaptation related to biological aging.

7. What is the Future?

It is quite evident that to some extent the future is already here. By considering the changes in the aging immune response, we are able to create efficient vaccines in older adults as demonstrated by the anti-herpes-zoster and the anti-COVID vaccines. Therefore, more knowledge is needed to create vaccines as efficient as those against other microbes, such as the HSV1, RSV, etc. We are on the right track, as many new mRNA vaccines are in the clinical trial pipeline. The development of new adjuvants is also mandatory to overcome in some circumstances the deleterious effect of excessive inflammaging. The reactivation of the exhausted T cells, if achievable, may be also a new avenue of improvement of vaccine efficacy, as was shown for checkpoint inhibitors in cancer treatment.

Again, the better way to design new, efficient vaccines is to better understand the aging immune response [76,87]. The new avenues to investigate in our comprehension in the immune changes are including the role of negative regulation by Tregs and my-eloid derived suppressor cells (MDSCs) [201-204]. We should not consider it only as a deleterious process, but as a dynamic process which tries to adapt the immune response to the new circumstances of longer life as well as towards the intensity and type of the stresses from inside and outside [205,206]. Thus, the immune response in aging should be considered as dynamically evolving between adaptation and maladaptation. There-fore, we should use what is adaptive and overcome what is maladaptive.

The new appreciation of frailty is also fundamental to be able to reinforce the immune response to vaccines of this part of the aging population [207]. The fact that frailty may be considered as a surrogate for biological aging may help to design interventions when the real biomarkers of this state will be known. New composite biomarkers (e.g., immune, physiological, laboratory and epigenetic) will help to better target the alterations.

More importantly, immune aging should be considered in the frame of a complex system [208]. A complex system is an open system that exchanges matter, energy and information with its environment (and possibly stores some of these), in such a way that it does useful work to be far from thermodynamic equilibrium. It is composed of multiple components whose interaction leads to the emergence of new behavior that each component alone cannot generate (i.e. its behavior is more than the sum of its parts). The interactions can be pairwise like in standard networks, but they can also be of higher order as in simplicial complexes and can change over time (i.e. plastic). Complex systems may have

different features, such as, multi-dimensional, spatial-temporal scale, nonlinear, spontaneous order, adaptation, feedback loops, among others [209,210]. For example, feedback loops in complex networks are distributed rather than centralised and provide a mechanism to stabilize or destabilise complex oscillations (or behaviour or function). Biological systems are endowed with several of these features and in particular with those that it allows to self-regulate (e.g., by making internal changes) or optimise by responding to changes from its environment. That is, biological systems are complex adaptive systems. Complex adaptive systems have the ability to synergistically combine internal and external (environmental) information, energy and matter in a way to optimise its performance, to evolutionary adapt and to survive (**Figure 2**). The immune system is such a system. We need a thorough study from this angle of the immune response of the older subjects. Recent studies tried to incorporate the many levels and layers from inside as well as from outside of the immune response. From these studies incorporating multi-omics approaches, AI tools, and other innovative approaches, a fuller picture will emerge helping to better understand the immune system's functioning and leading to the creation of new vaccines [211-216].


Figure 2. When we go from young adults to old adults, we experience immunosenescence and inflammaging, which impact on our response to vaccinations, making it suboptimal (red track). However, if the studies of mechanisms of aging (esp. immune system aging) would give us the targets (described in the text) we may intervene on one hand into the processes of inflammaging and immunosenescence, and on the other by modifying the vaccine to suit better the old subjects (green track).

8. Conclusion and Perspective

Contrary to the general view of the degeneration of the immune response with aging, new studies demonstrate that it is concomitantly adaptive and maladaptive. The outcome depends on the balance of these two entities. The new vaccine successes in older populations also reinforce that reserves still exist which may be exploited by new vaccines. They can build concomitantly to the vaccine improvement by exploiting the mechanisms of senescence, exhaustion, memory development as well as trained innate immunity [219-223].

Future vaccines will probably build on our knowledge and will lead to immunologically and clinically efficient vaccines. Besides well-known changes in composition, adding of adjuvants, or the changes in doses, more mechanistic interventions may be perhaps implemented, such as the use of IL-7, the modulation of transcription factors and/or noncoding RNAs by the CRISPR technologies, and the use of computational models to design better vaccine targets to build on what is functioning rather than only considering what is not.

Conflict of interest: The authors declare that they have no conflict of interest related to this article, except AAC who is founder and CEO at Oken.

References

1. Plotkin S. History of vaccination. Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12283-7. doi: 10.1073/pnas.1400472111.
2. Wagner A, Weinberger B. Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives. Front Immunol. 2020 Apr 23;11:717. doi: 10.3389/fimmu.2020.00717.
3. Cunningham AL, McIntyre P, Subbarao K, Booy R, Levin MJ. Vaccines for older adults. BMJ. 2021 Feb 22;372:n188. doi: 10.1136/bmj.n188.
4. Weinberger B. Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. Immun Ageing. 2021 Oct 9;18(1):38. doi: 10.1186/s12979-021-00249-6.
5. Mallapaty S. The coronavirus is most deadly if you are older and male - new data reveal the risks. Nature. 2020 Sep;585(7823):16-17. doi: 10.1038/d41586-020-02483-2.
6. Gustafson CE, Kim C, Weyand CM, Goronzy JJ. Influence of immune aging on vaccine responses. J Allergy Clin Immunol. 2020 May;145(5):1309-1321. doi: 10.1016/j.jaci.2020.03.017.
7. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, Belanger S, Abbott RK, Kim C, Choi J, Kato Y, Crotty EG, Kim C, Rawlings SA, Mateus J, Tse LPV, Frazier A, Baric R, Peters B, Greenbaum J, Ollmann Saphire E, Smith DM, Sette A, Crotty S. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020 Nov 12;183(4):996-1012.e19. doi: 10.1016/j.cell.2020.09.038.
8. Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, Alanio C, Kuri-Cervantes L, Pampena MB, D'Andrea K, Manne S, Chen Z, Huang YJ, Reilly JP, Weisman AR, Ittner CAG, Kuthuru O, Dougherty J, Nzingha K, Han N, Kim J, Pattekar A, Goodwin EC, Anderson EM, Weirick ME, Gouma S, Arevalo CP, Bolton MJ, Chen F, Lacey SF, Ramage H, Cherry S, Hensley SE, Apostolidis SA, Huang AC, Vella LA; UPenn COVID Processing Unit, Betts MR, Meyer NJ, Wherry EJ. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020 Sep 4;369(6508):eabc8511. doi: 10.1126/science.abc8511.
9. Akbar AN, Gilroy DW. Aging immunity may exacerbate COVID-19. Science. 2020 Jul 17;369(6501):256-257. doi: 10.1126/science.abb0762.
10. Channappanavar R, Perlman S.J Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity. Clin Invest. 2020 Dec 1;130(12):6204-6213.
11. Meftahi GH, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging". Inflamm Res. 2020 Sep;69(9):825-839. doi: 10.1007/s00011-020-01372-8.
12. Deans GD, Stiver HG, McElhaney JE. Influenza vaccines provide diminished protection but are cost-saving in older adults. J Intern Med. 2010 Feb;267(2):220-7. doi: 10.1111/j.1365-2796.2009.02201.x.
13. McElhaney JE, Effros RB.Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol. 2009 Aug;21(4):418-24. doi: 10.1016/j.coi.2009.05.023.

14. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW; Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003 May 1;348(18):1747-55. doi: 10.1056/NEJMoa022678.

15. Pawelec G. Age and immunity: What is "immunosenescence"? Exp Gerontol. 2018 May;105:4-9. doi: 10.1016/j.exger.2017.10.024.

16. Müller L, Di Benedetto S, Pawelec G. The Immune System and Its Dysregulation with Aging. Subcell Biochem. 2019;91:21-43. doi: 10.1007/978-981-13-3681-2_2.

17. Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000 Jun;908:244-54. doi: 10.1111/j.1749-6632.2000.tb06651.x.

18. Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, Witkowski JM, Franceschi C. Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? Front Immunol. 2018 Jan 10;8:1960. doi: 10.3389/fimmu.2017.01960.

19. Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: The challenge of immune changes with aging. Semin Immunol. 2018 Dec;40:83-94. doi: 10.1016/j.smim.2018.10.010.

20. Franceschi C, Salvioli S, Garagnani P, de Eguileor M, Monti D, Capri M. Immunobiography and the Heterogeneity of Immune Responses in the Elderly: A Focus on Inflammaging and Trained Immunity. Front Immunol. 2017 Aug 15;8:982. doi: 10.3389/fimmu.2017.00982.

21. Andrew MK, Shinde V, Ye L, Hatchette T, Haguinet F, Dos Santos G, McElhaney JE, Ambrose A, Boivin G, Bowie W, Chit A, ElSherif M, Green K, Halperin S, Ibarguchi B, Johnstone J, Katz K, Langley J, Leblanc J, Loeb M, MacKinnon-Cameron D, McCarthy A, McGeer A, Powis J, Richardson D, Semret M, Stiver G, Trottier S, Valiquette L, Webster D, McNeil SA; Serious Outcomes Surveillance Network of the Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) and the Toronto Invasive Bacterial Diseases Network (TIBDN). The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People. J Infect Dis. 2017 Aug 15;216(4):405-414. doi: 10.1093/infdis/jix282.

22. McElhaney JE, Zhou X, Talbot HK, Soethout E, Bleackley RC, Granville DJ, Pawelec G. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine. 2012 Mar 9;30(12):2060-7. doi: 10.1016/j.vaccine.2012.01.015.

23. Canouï E, Launay O. History and principles of vaccination. Rev Mal Respir. 2019 Jan;36(1):74-81. doi: 10.1016/j.rmr.2018.02.015.

24. Zepp F. Principles of Vaccination. Methods Mol Biol. 2016;1403:57-84. doi: 10.1007/978-1-4939-3387-7_3.

25. Cakala-Jakimowicz M, Kolodziej-Wojnar P, Puzianowska-Kuznicka M. Aging-Related Cellular, Structural and Functional Changes in the Lymph Nodes: A Significant Component of Immunosenescence? An Overview. Cells. 2021 Nov 12;10(11):3148. doi: 10.3390/cells10113148.

26. Moser M, Leo O. Key concepts in immunology. Vaccine. 2010 Aug 31;28 Suppl 3:C2-13. doi: 10.1016/j.vaccine.2010.07.022.

27. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell. 2001 Aug 10;106(3):263-6. doi: 10.1016/s0092-8674(01)00455-x.

28. Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature. 2004 Jan 8;427(6970):154-9. doi: 10.1038/nature02238.

29. van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol. 2006 Jan;27(1):49-55. doi: 10.1016/j.it.2005.11.005.

30. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev. 2004 Jun;199:227-50. doi: 10.1111/j.0105-2896.2004.00144.x.

31. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010 Jul;17(7):1055-65. doi: 10.1128/CVI.00131-10.

32. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol. 2005 Jun;17(3):326-32. doi: 10.1016/j.coi.2005.04.010.

33. Jelley-Gibbs DM, Strutt TM, McKinstry KK, Swain SL. Influencing the fates of CD4 T cells on the path to memory: lessons from influenza. Immunol Cell Biol. 2008 May-Jun;86(4):343-52. doi: 10.1038/icb.2008.13.

34. Yamane H, Paul WE. Early signaling events that underlie fate decisions of naive CD4(+) T cells toward distinct T-helper cell subsets. Immunol Rev. 2013 Mar;252(1):12-23. doi: 10.1111/imr.12032.

35. Nakayamada S, Takahashi H, Kanno Y, O'Shea JJ. Helper T cell diversity and plasticity. Curr Opin Immunol. 2012 Jun;24(3):297-302. doi: 10.1016/j.coi.2012.01.014.

36. Pepper M, Jenkins MK. Origins of CD4(+) effector and central memory T cells. Nat Immunol. 2011 Jun;12(6):467-71. doi: 10.1038/ni.2038.

37. Ciabattini A, Pettini E, Medaglini D. CD4(+) T Cell Priming as Biomarker to Study Immune Response to Preventive Vaccines. Front Immunol. 2013 Dec 4;4:421. doi: 10.3389/fimmu.2013.00421.

38. Gasper DJ, Tejera MM, Suresh M. CD4 T-cell memory generation and maintenance. Crit Rev Immunol. 2014;34(2):121-46. doi: 10.1615/critrevimmunol.2014010373.

39. Allen CD, Cyster JG. Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin Immunol. 2008 Feb;20(1):14-25. doi: 10.1016/j.smim.2007.12.001.

40. Eibel H, Kraus H, Sic H, Kienzler AK, Rizzi M. B cell biology: an overview. Curr Allergy Asthma Rep. 2014 May;14(5):434. doi: 10.1007/s11882-014-0434-8.

41. 41 Samji T, Khanna KM. Understanding memory CD8+ T cells. Immunol Lett. 2017 May;185:32-39. doi: 10.1016/j.imlet.2017.02.012.

42. Arai Y, Martin-Ruiz CM, Takayama M, Abe Y, Takebayashi T, Koyasu S, Suematsu M, Hirose N, von Zglinicki T. Inflammation, But Not Telomere Length, Predicts Successful Ageing at Extreme Old Age: A Longitudinal Study of Semi-supercentenarians. EBioMedicine. 2015 Jul 29;2(10):1549-58. doi: 10.1016/j.ebiom.2015.07.029.

43. Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, Witkowski JM, Franceschi C. Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? Front Immunol. 2018 Jan 10;8:1960. doi: 10.3389/fimmu.2017.01960.

44. Franceschi C, Garagnani P, Morsiani C, Conte M, Santoro A, Grignolio A, Monti D, Capri M, Salvioli S. The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different. Front Med (Lausanne). 2018 Mar 12;5:61. doi: 10.3389/fmed.2018.00061.

45. Fahy GM, Brooke RT, Watson JP, Good Z, Vasanawala SS, Maecker H, Leipold MD, Lin DTS, Kobor MS, Horvath S. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell. 2019 Dec;18(6):e13028. doi: 10.1111/acel.13028.

46. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, Hou L, Baccarelli AA, Stewart JD, Li Y, Whitsel EA, Wilson JG, Reiner AP, Aviv A, Lohman K, Liu Y, Ferrucci L, Horvath S. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018 Apr 18;10(4):573-591. doi: 10.18632/aging.101414.

47. Belsky DW, Caspi A, Houts R, Cohen HJ, Corcoran DL, Danese A, Harrington H, Israel S, Levine ME, Schaefer JD, Sugden K, Williams B, Yashin AI, Poulton R, Moffitt TE. Quantification of biological aging in young adults. Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4104-10. doi: 10.1073/pnas.1506264112.

48. Fulop T, Larbi A, Pawelec G, Khalil A, Cohen AA, Hirokawa K, Witkowski JM, Franceschi C. Immunology of Aging: the Birth of Inflammaging. Clin Rev Allergy Immunol. 2021 Sep 18:1-14. doi: 10.1007/s12016-021-08899-6.

49. Diebel LWM, Rockwood K. Determination of Biological Age: Geriatric Assessment vs Biological Biomarkers. Curr Oncol Rep. 2021 Jul 16;23(9):104. doi: 10.1007/s11912-021-01097-9.

50. Dhillon BK, Smith M, Baghela A, Lee AHY, Hancock REW. Systems Biology Approaches to Understanding the Human Immune System. Front Immunol. 2020 Jul 30;11:1683. doi: 10.3389/fimmu.2020.01683.

51. Lambert ND, Ovsyannikova IG, Pankratz VS, Jacobson RM, Poland GA. Understanding the immuneresponse to seasonal influenza vaccination in older adults: a systems biology approach. Expert Rev Vaccines. 2012 Aug;11(8):985-94. doi: 10.1586/erv.12.61.

52. Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence: A systems-level overview of immune cell biology and strategies for improving vaccine responses. Exp Gerontol. 2019 Sep;124:110632. doi: 10.1016/j.exger.2019.110632.

53. Pulendran B, Davis MM. The science and medicine of humanimmunology. Science. 2020 Sep 25;369(6511):eaay4014. doi: 10.1126/science.aay4014.

54. Goudsmit J, van den Biggelaar AHJ, Koudstaal W, Hofman A, Koff WC, Schenkelberg T, Alter G, Mina MJ, Wu JW.Immune age and biological age as determinants of vaccine responsiveness among elderly populations: the Human Immunomics Initiative research program. Eur J Epidemiol. 2021 Jul;36(7):753-762. doi: 10.1007/s10654-021-00767-z.

55. Nikolich-Žugich J, Bradshaw CM, Uhrlaub JL, Watanabe M. Immunity to acute virus infections with advanced age. Curr Opin Virol. 2021 Feb;46:45-58. doi: 10.1016/j.coviro.2020.09.007.

56. Niwa Y, Kasama T, Miyachi Y, Kanoh T. Neutrophil chemotaxis, phagocytosis and parameters of reactive oxygen species in human aging: cross-sectional and longitudinal studies. Life Sci. 1989;44(22):1655-64. doi: 10.1016/0024-3205(89)90482-7.

57. Wenisch C, Patruta S, Daxböck F, Krause R, Hörl W. Effect of age on human neutrophil function. J Leukoc Biol. 2000 Jan;67(1):40-5. doi: 10.1002/jlb.67.1.40.

58. Agrawal A, Agrawal S, Gupta S. Role of Dendritic Cells in Inflammation and Loss of Tolerance in the Elderly. Front Immunol. 2017 Jul 26;8:896. doi: 10.3389/fimmu.2017.00896.

59. Plowden J, Renshaw-Hoelscher M, Engleman C, Katz J, Sambhara S. Innate immunity in aging: impact on macrophage function. Aging Cell. 2004 Aug;3(4):161-7. doi: 10.1111/j.1474-9728.2004.00102.x.

60. Campos C, Pera A, Lopez-Fernandez I, Alonso C, Tarazona R, Solana R. Proinflammatory status influences NK cells subsets in the elderly. Immunol Lett. 2014 Nov;162(1 Pt B):298-302. doi: 10.1016/j.imlet.2014.06.015.

61. Mace EM, Orange JS. Emerging insights into human health and NK cell biology from the study of NK cell deficiencies. Immunol Rev. 2019 Jan;287(1):202-225. doi: 10.1111/imr.12725.

62. Fülöp T, Larbi A, Witkowski JM. Human Inflammaging. Gerontology. 2019;65(5):495-504. doi: 10.1159/000497375.

63. Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T. Innate immunosenescence: effect of aging on cells and receptors of the innateimmunesystem in humans. Semin Immunol. 2012 Oct;24(5):331-41. doi: 10.1016/j.smim.2012.04.008.

64. Fortin CF, Lesur O, Fulop T Jr. Effects of TREM-1 activation in human neutrophils: activation of signaling pathways, recruitment into lipid rafts and association with TLR4. Int Immunol. 2007 Jan;19(1):41-50. doi: 10.1093/intimm/dxl119.

65. Metcalf TU, Cubas RA, Ghneim K, Cartwright MJ, Grevenynghe JV, Richner JM, Olagnier DP, Wilkinson PA, Cameron MJ, Park BS, Hiscott JB, Diamond MS, Wertheimer AM, Nikolich-Zugich J, Haddad EK. Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors. Aging Cell. 2015 Jun;14(3):421-32. doi: 10.1111/acel.12320.

66. Balan S, Saxena M, Bhardwaj N. Dendritic cell subsets and locations. Int Rev Cell Mol Biol. 2019;348:1-68. doi: 10.1016/bs.ircmb.2019.07.004.

67. Gupta S. Role of dendriticn cells in innate and adaptive immune response in humanaging. Exp Gerontol. 2014 Jun;54:47-52. doi: 10.1016/j.exger.2013.12.009.

68. Borges RC, Hohmann MS, Borghi SM. Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome. Int Rev Immunol. 2021;40(1-2):108-125. doi: 10.1080/08830185.2020.1844195.

69. Agrawal A, Agrawal S, Gupta S. Dendritic cells in human aging. Exp Gerontol. 2007 May;42(5):421-6. doi: 10.1016/j.exger.2006.11.007.

70. Hadamitzky C, Spohr H, Debertin AS, Guddat S, Tsokos M, Pabst R. Age-dependent histoarchitectural changes in human lymph nodes: an underestimated process with clinical relevance? J Anat. 2010 May;216(5):556-62. doi: 10.1111/j.1469-7580.2010.01213.x.

71. Sridharan A, Esposo M, Kaushal K, Tay J, Osann K, Agrawal S, Gupta S, Agrawal A. Age-associated impaired plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T cell immunity. Age (Dordr). 2011 Sep;33(3):363-76. doi: 10.1007/s11357-010-9191-3.

72. Briceño O, Lissina A, Wanke K, Afonso G, von Braun A, Ragon K, Miquel T, Gostick E, Papagno L, Stiasny K, Price DA, Mallone R, Sauce D, Karrer U, Appay V.Reduced naïve CD8(+) T-cell priming efficacy in elderly adults. Aging Cell. 2016 Feb;15(1):14-21. doi: 10.1111/acel.12384.

73. Lazuardi L, Jenewein B, Wolf AM, Pfister G, Tzankov A, Grubeck-Loebenstein B. Age-related loss of naïve T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology. 2005 Jan;114(1):37-43. doi: 10.1111/j.1365-2567.2004.02006.x.

74. Czesnikiewicz-Guzik M, Lee WW, Cui D, Hiruma Y, Lamar DL, Yang ZZ, Ouslander JG, Weyand CM, Goronzy JJ. T cell subset-specific susceptibility to aging. Clin Immunol. 2008 Apr;127(1):107-18. doi: 10.1016/j.clim.2007.12.002.

75. Whiting CC, Siebert J, Newman AM, Du HW, Alizadeh AA, Goronzy J, Weyand CM, Krishnan E, Fathman CG, Maecker HT. Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging. PLoS One. 2015 Jul 21;10(7):e0133627. doi: 10.1371/journal.pone.0133627.

76. Hakim FT, Gress RE. Immunosenescence: deficits in adaptive immunity in the elderly. Tissue Antigens. 2007 Sep;70(3):179-89. doi: 10.1111/j.1399-0039.2007.00891.x.

77. Zhang H, Weyand CM, Goronzy JJ, Gustafson CE. Understanding T cell aging to improve anti-viral immunity. Curr Opin Virol. 2021 Dec;51:127-133. doi: 10.1016/j.coviro.2021.09.017.

78. Dugan HL, Henry C, Wilson PC. Aging and influenza vaccine-induced immunity. Cell Immunol. 2020 Feb;348:103998. doi: 10.1016/j.cellimm.2019.103998.

79. Chidrawar S, Khan N, Wei W, McLarnon A, Smith N, Nayak L, Moss P. Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals. Clin Exp Immunol. 2009 Mar;155(3):423-32. doi: 10.1111/j.1365-2249.2008.03785.x.

80. Pinti M, Appay V, Campisi J, Frasca D, Fülöp T, Sauce D, Larbi A, Weinberger B, Cossarizza A. Aging of the immune system: Focus on inflammation and vaccination. Eur J Immunol. 2016 Oct;46(10):2286-2301. doi: 10.1002/eji.201546178.

81. Longo DM, Louie B, Putta S, Evensen E, Ptacek J, Cordeiro J, Wang E, Pos Z, Hawtin RE, Marincola FM, Cesano A. Single-cell network profiling of peripheral blood mononuclear cells from healthy donors reveals age- and race-associated differences in immune signaling pathway activation. J Immunol. 2012 Feb 15;188(4):1717-25. doi: 10.4049/jimmunol.1102514.

82. Shen-Orr SS, Furman D, Kidd BA, Hadad F, Lovelace P, Huang YW, Rosenberg-Hasson Y, Mackey S, Grisar FA, Pickman Y, Maecker HT, Chien YH, Dekker CL, Wu JC, Butte AJ, Davis MM. Defective Signaling in the JAK-STAT Pathway Tracks with Chronic Inflammation and Cardiovascular Risk in Aging Humans. Cell Syst. 2016 Oct 26;3(4):374-384.e4. doi: 10.1016/j.cels.2016.09.009.

83. Li G, Ju J, Weyand CM, Goronzy JJ. Age-Associated Failure To Adjust Type I IFN Receptor Signaling Thresholds after T Cell Activation. J Immunol. 2015 Aug 1;195(3):865-74. doi: 10.4049/jimmunol.1402389.

84. Pereira BI, De Maeyer RPH, Covre LP, Nehar-Belaid D, Lanna A, Ward S, Marches R, Chambers ES, Gomes DCO, Riddell NE, Maini MK, Teixeira VH, Janes SM, Gilroy DW, Larbi A, Mabbott NA, Ucar D, Kuchel GA, Henson SM, Strid J, Lee JH, Banchereau J, Akbar AN. Sestrins induce natural killer function in senescent-like CD8+ T cells. Nat Immunol. 2020 Jun;21(6):684-694. doi: 10.1038/s41590-020-0643-3.

85. Mogilenko DA, Shpynov O, Andhey PS, Arthur L, Swain A, Esaulova E, Brioschi S, Shchukina I, Kerndl M, Bambouskova M, Yao Z, Laha A, Zaitsev K, Burdess S, Gillfilan S, Stewart SA, Colonna M, Artyomov MN. Comprehensive Profiling of an Aging Immune System Reveals Clonal GZMK+ CD8+ T Cells as Conserved Hallmark of Inflammaging. Immunity. 2021 Jan 12;54(1):99-115.e12. doi: 10.1016/j.immuni.2020.11.005.

86. Jameson SC, Masopust D. Understanding Subset Diversity in T Cell Memory. Immunity. 2018 Feb 20;48(2):214-226. doi: 10.1016/j.immuni.2018.02.010.

87. Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, Pawelec G. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing. 2008 Jul 25;5:6. doi: 10.1186/1742-4933-5-6.

88. Zhang H, Weyand CM, Goronzy JJ. Hallmarks of the aging T-cell system. FEBS J. 2021 Dec;288(24):7123-7142. doi: 10.1111/febs.15770.

89. Goronzy JJ, Weyand CM. Mechanisms underlying T cell ageing. Nat Rev Immunol. 2019 Sep;19(9):573-583. doi: 10.1038/s41577-019-0180-1.

90. Hu B, Li G, Ye Z, Gustafson CE, Tian L, Weyand CM, Goronzy JJ. Transcription factor networks in aged naïve CD4 T cells bias lineage differentiation. Aging Cell. 2019 Aug;18(4):e12957. doi: 10.1111/acel.12957.

91. Jeng MY, Hull PA, Fei M, Kwon HS, Tsou CL, Kasler H, Ng CP, Gordon DE, Johnson J, Krogan N, Verdin E, Ott M. Metabolic reprogramming of human CD8+ memory T cells through loss of SIRT1. J Exp Med. 2018 Jan 2;215(1):51-62. doi: 10.1084/jem.20161066.

92. Weng NP, Akbar AN, Goronzy J. CD28(-) T cells: their role in the age-associated decline of immune function. Trends Immunol. 2009 Jul;30(7):306-12. doi: 10.1016/j.it.2009.03.013.

93. Larbi A, Fulop T. From "truly naïve" to "exhausted senescent" T cells: when markers predict functionality. Cytometry A. 2014 Jan;85(1):25-35. doi: 10.1002/cyto.a.22351.

94. Fülöp T, Larbi A, Pawelec G. Human T cell aging and the impact of persistent viral infections. Front Immunol. 2013 Sep 13;4:271. doi: 10.3389/fimmu.2013.00271.

95. Brunner S, Herndler-Brandstetter D, Weinberger B, Grubeck-Loebenstein B. Persistent viral infections and immune aging. Ageing Res Rev. 2011 Jul;10(3):362-9. doi: 10.1016/j.arr.2010.08.003.

96. Mueller SN, Mackay LK. Tissue-resident memory T cells: local specialists in immune defence. Nat Rev Immunol. 2016 Feb;16(2):79-89. doi: 10.1038/nri.2015.3.

97. Alpert A, Pickman Y, Leipold M, Rosenberg-Hasson Y, Ji X, Gaujoux R, Rabani H, Starosvetsky E, Kveler K, Schaffert S, Furman D, Caspi O, Rosenschein U, Khatri P, Dekker CL, Maecker HT, Davis MM, Shen-Orr SS. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. Nat Med. 2019 Mar;25(3):487-495. doi: 10.1038/s41591-019-0381-y.

98. Nikolich-Zugich J, Rudd BD. Immune memory and aging: an infinite or finite resource? Curr Opin Immunol. 2010 Aug;22(4):535-40. doi: 10.1016/j.coi.2010.06.011.

99. Pawelec G, Bronikowski A, Cunnane SC, Ferrucci L, Franceschi C, Fülöp T, Gaudreau P, Gladyshev VN, Gonos ES, Gorbunova V, Kennedy BK, Larbi A, Lemaître JF, Liu GH, Maier AB, Morais JA, Nóbrega OT, Moskalev A, Rikkert MO, Seluanov A, Senior AM, Ukraintseva S, Vanhaelen Q, Witkowski J, Cohen AA. The conundrum of human immune system "senescence". Mech Ageing Dev. 2020 Dec;192:111357. doi: 10.1016/j.mad.2020.111357.

100. Monti D, Ostan R, Borelli V, Castellani G, Franceschi C. Inflammaging and human longevity in the omics era. Mech Ageing Dev. 2017 Jul;165(Pt B):129-138. doi: 10.1016/j.mad.2016.12.008.

101. Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: The challenge of immune changes with aging. Semin Immunol. 2018 Dec;40:83-94. doi: 10.1016/j.smim.2018.10.010.

102. Santoro A, Bientinesi E, Monti D. Immunosenescence and inflammaging in the aging process: age-related diseases or longevity? Ageing Res Rev. 2021 Nov;71:101422. doi: 10.1016/j.arr.2021.101422.

103. Frasca D, Diaz A, Romero M, Garcia D, Blomberg BB.B Cell Immunosenescence. Annu Rev Cell Dev Biol. 2020 Oct 6;36:551-574. doi: 10.1146/annurev-cellbio-011620-034148.

104. Frasca D, Blomberg BB, Garcia D, Keilich SR, Haynes L. Age-related factors that affect B cell responses to vaccination in mice and humans. Immunol Rev. 2020 Jul;296(1):142-154. doi: 10.1111/imr.12864.

105. Cancro MP, Hao Y, Scholz JL, Riley RL, Frasca D, Dunn-Walters DK, Blomberg BB. B cells and aging: molecules and mechanisms. Trends Immunol. 2009 Jul;30(7):313-8. doi: 10.1016/j.it.2009.04.005.

106. Frasca D. Senescent B cells in aging and age-related diseases: Their role in the regulation of antibody responses. Exp Gerontol. 2018 Jul 1;107:55-58. doi: 10.1016/j.exger.2017.07.002.

107. Frasca D, Blomberg BB. Aging induces B cell defects and decreased antibody responses to influenza infection and vaccination. Immun Ageing. 2020 Nov 19;17(1):37. doi: 10.1186/s12979-020-00210-z.

108. Pritz T, Lair J, Ban M, Keller M, Weinberger B, Krismer M, Grubeck-Loebenstein B. Plasma cell numbers decrease in bone marrow of old patients. Eur J Immunol. 2015 Mar;45(3):738-46. doi: 10.1002/eji.201444878.

109. Gibson KL, Wu YC, Barnett Y, Duggan O, Vaughan R, Kondeatis E, Nilsson BO, Wikby A, Kipling D, Dunn-Walters DK. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell. 2009 Feb;8(1):18-25. doi: 10.1111/j.1474-9726.2008.00443.x.

110. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol. 2009 Mar;9(3):185-94. doi: 10.1038/nri2508.

111. Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, Ligotti ME, Zareian N, Accardi G. Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention. Front Immunol. 2019 Sep 25;10:2247. doi: 10.3389/fimmu.2019.02247.

112. Sen P, Shah PP, Nativio R, Berger SL. Epigenetic Mechanisms of Longevity and Aging. Cell. 2016 Aug 11;166(4):822-839. doi: 10.1016/j.cell.2016.07.050.

113. Horvath S, Raj K. DNA methylation-based biomarkers and the epigeneticclock theory of ageing. Nat Rev Genet. 2018 Jun;19(6):371-384. doi: 10.1038/s41576-018-0004-3.

114. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115. doi: 10.1186/gb-2013-14-10-r115.

115. Hu B, Jadhav RR, Gustafson CE, Le Saux S, Ye Z, Li X, Tian L, Weyand CM, Goronzy JJ. Distinct Age-Related Epigenetic Signatures in CD4 and CD8 T Cells. Front Immunol. 2020 Nov 11;11:585168. doi: 10.3389/fimmu.2020.585168.

116. Ucar D, Márquez EJ, Chung CH, Marches R, Rossi RJ, Uyar A, Wu TC, George J, Stitzel ML, Palucka AK, Kuchel GA, Banchereau J. The chromatin accessibility signature of human immune aging stems from CD8+ T cells. J Exp Med. 2017 Oct 2;214(10):3123-3144. doi: 10.1084/jem.20170416.

117. Moskowitz DM, Zhang DW, Hu B, Le Saux S, Yanes RE, Ye Z, Buenrostro JD, Weyand CM, Greenleaf WJ, Goronzy JJ. Epigenomics of human CD8 T cell differentiation and aging. Sci Immunol. 2017 Feb;2(8):eaag0192. doi: 10.1126/sciimmunol.aag0192.

118. Akbar AN, Beverley PC, Salmon M. Will telomere erosion lead to a loss of T-cell memory? Nat Rev Immunol. 2004 Sep;4(9):737-43.

119. Libertini G, Shubernetskaya O, Corbi G, Ferrara N. Is Evidence Supporting the Subtelomere-Telomere Theory of Aging? Biochemistry (Mosc). 2021 Dec;86(12):1526-1539. doi: 10.1134/S0006297921120026.

120. Bektas A, Zhang Y, Lehmann E, Wood WH 3rd, Becker KG, Madara K, Ferrucci L, Sen R. Age-associated changes in basal NF-κB function in human CD4+ T lymphocytes via dysregulation of PI3 kinase. Aging (Albany NY). 2014 Nov;6(11):957-74. doi: 10.18632/aging.100705.

121. Bharath LP, Agrawal M, McCambridge G, Nicholas DA, Hasturk H, Liu J, Jiang K, Liu R, Guo Z, Deeney J, Apovian CM, Snyder-Cappione J, Hawk GS, Fleeman RM, Pihl RMF, Thompson K, Belkina AC, Cui L, Proctor EA, Kern PA, Nikolajczyk BS. Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated Inflammation. Cell Metab. 2020 Jul 7;32(1):44-55.e6. doi: 10.1016/j.cmet.2020.04.015.

122. Geltink RIK, Kyle RL, Pearce EL. Unraveling the Complex Interplay Between T Cell Metabolism and Function. Annu Rev Immunol. 2018 Apr 26;36:461-488. doi: 10.1146/annurev-immunol-042617-053019.

123. Li G, Yu M, Lee WW, Tsang M, Krishnan E, Weyand CM, Goronzy JJ. Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nat Med. 2012 Oct;18(10):1518-24. doi: 10.1038/nm.2963.

124. Le Page A, Fortin C, Garneau H, Allard N, Tsvetkova K, Tan CT, Larbi A, Dupuis G, Fülöp T. Downregulation of inhibitory SRC homology 2 domain-containing phosphatase-1 (SHP-1) leads to recovery of T cell responses in elderly. Cell Commun Signal. 2014 Jan 9;12:2. doi: 10.1186/1478-811X-12-2.

125. Fulop T, Le Page A, Fortin C, Witkowski JM, Dupuis G, Larbi A. Cellular signaling in the aging immune system. Curr Opin Immunol. 2014 Aug;29:105-11. doi: 10.1016/j.coi.2014.05.007.

126. Larbi A, Dupuis G, Khalil A, Douziech N, Fortin C, Fülöp T Jr. Differential role of lipid rafts in the functions of CD4+ and CD8+ human T lymphocytes with aging. Cell Signal. 2006 Jul;18(7):1017-30. doi: 10.1016/j.cellsig.2005.08.016.

127. Smigielska-Czepiel K, van den Berg A, Jellema P, Slezak-Prochazka I, Maat H, van den Bos H, van der Lei RJ, Kluiver J, Brouwer E, Boots AM, Kroesen BJ. Dual role of miR-21 in CD4+ T-cells: activation-induced miR-21 supports survival of memory T-cells and regulates CCR7 expression in naive T-cells. PLoS One. 2013 Oct 1;8(10):e76217. doi: 10.1371/journal.pone.0076217.

128. Kim C, Hu B, Jadhav RR, Jin J, Zhang H, Cavanagh MM, Akondy RS, Ahmed R, Weyand CM, Goronzy JJ. Activation of miR-21-Regulated Pathways in Immune Aging Selects against Signatures Characteristic of Memory T Cells. Cell Rep. 2018 Nov 20;25(8):2148-2162.e5. doi: 10.1016/j.celrep.2018.10.074.

129. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, Cevenini E, Castellani GC, Salvioli S. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007 Jan;128(1):92-105. doi: 10.1016/j.mad.2006.11.016.

130. Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, Witkowski JM, Franceschi C. Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? Front Immunol. 2018 Jan 10;8:1960. doi: 10.3389/fimmu.2017.01960.

131. Fulop T, Witkowski JM, Olivieri F, Larbi A. The integration of inflammaging in age-related diseases. Semin Immunol. 2018 Dec;40:17-35. doi: 10.1016/j.smim.2018.09.003.

132. Fourati S, Cristescu R, Loboda A, Talla A, Filali A, Railkar R, Schaeffer AK, Favre D, Gagnon D, Peretz Y, Wang IM, Beals CR, Casimiro DR, Carayannopoulos LN, Sékaly RP. Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination. Nat Commun. 2016 Jan 8;7:10369. doi: 10.1038/ncomms10369.

133. Vukmanovic-Stejic M, Chambers ES, Suárez-Fariñas M, Sandhu D, Fuentes-Duculan J, Patel N, Agius E, Lacy KE, Turner CT, Larbi A, Birault V, Noursadeghi M, Mabbott NA, Rustin MHA, Krueger JG, Akbar AN. Enhancement of cutaneous immunity during aging by blocking p38 mitogen-activated protein (MAP) kinase-induced inflammation. J Allergy Clin Immunol. 2018 Sep;142(3):844-856. doi: 10.1016/j.jaci.2017.10.032.

134. Pereira B, Xu XN, Akbar AN. Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly. Front Immunol. 2020 Oct 14;11:583019. doi: 10.3389/fimmu.2020.583019.

135. Qi Q, Liu Y, Cheng Y, Glanville J, Zhang D, Lee JY, Olshen RA, Weyand CM, Boyd SD, Goronzy JJ. Diversity and clonal selection in the human T-cell repertoire. Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13139-44. doi: 10.1073/pnas.1409155111.

136. Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, Riddell SR, Warren EH, Carlson CS. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009 Nov 5;114(19):4099-107. doi: 10.1182/blood-2009-04-217604.

137. de Greef PC, Oakes T, Gerritsen B, Ismail M, Heather JM, Hermsen R, Chain B, de Boer RJ. The naive T-cell receptor repertoire has an extremely broad distribution of clone sizes. Elife. 2020 Mar 18;9:e49900. doi: 10.7554/eLife.49900.

138. Drabkin MJ, Meyer JI, Kanth N, Lobel S, Fogel J, Grossman J, Krumenacker JH. Age-stratified Patterns of Thymic Involution on Multidetector CT. J Thorac Imaging. 2018 Nov;33(6):409-416. doi: 10.1097/RTI.0000000000000349.

139. Mold JE, Réu P, Olin A, Bernard S, Michaëlsson J, Rane S, Yates A, Khosravi A, Salehpour M, Possnert G, Brodin P, Frisén J. Cell generation dynamics underlying naive T-cell homeostasis in adult humans. PLoS Biol. 2019 Oct 29;17(10):e3000383. doi: 10.1371/journal.pbio.3000383.

140. Nicoli F, Clave E, Wanke K, von Braun A, Bondet V, Alanio C, Douay C, Baque M, Lependu C, Marconi P, Stiasny K, Heinz FX, Muetsch M, Duffy D, Boddaert J, Sauce D, Toubert A, Karrer U, Appay V. Primary immune responses are negatively impacted by persistent herpesvirus infections in older people: results from an observational study on healthy subjects and a vaccination trial on subjects aged more than 70 years old. EBioMedicine. 2022 Feb;76:103852. doi: 10.1016/j.ebiom.2022.103852.

141. Britanova OV, Putintseva EV, Shugay M, Merzlyak EM, Turchaninova MA, Staroverov DB, Bolotin DA, Lukyanov S, Bogdanova EA, Mamedov IZ, Lebedev YB, Chudakov DM. Age-related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling. J Immunol. 2014 Mar 15;192(6):2689-98. doi: 10.4049/jimmunol.1302064.

142. Horn V, Semmler M, Schweppe C. Older People in Germany During the COVID-19 Pandemic:The Least, the More, and the Most Affected. J Popul Ageing. 2021 Dec 13:1-22. doi: 10.1007/s12062-021-09352-4.

143. Maltese G, Corsonello A, Di Rosa M, Soraci L, Vitale C, Corica F, Lattanzio F. Frailty and COVID-19: A Systematic Scoping Review. J Clin Med. 2020 Jul 4;9(7):2106. doi: 10.3390/jcm9072106.

144. De Smet R, Mellaerts B, Vandewinckele H, Lybeert P, Frans E, Ombelet S, Lemahieu W, Symons R, Ho E, Frans J, Smismans A, Laurent MR. Frailty and Mortality in Hospitalized Older Adults With COVID-19: Retrospective Observational Study. J Am Med Dir Assoc. 2020 Jul;21(7):928-932.e1. doi: 10.1016/j.jamda.2020.06.008.

145. Fulop T, Dupuis G, Baehl S, Le Page A, Bourgade K, Frost E, Witkowski JM, Pawelec G, Larbi A, Cunnane S. From inflamm-aging to immune-paralysis: a slippery slope during aging for immune-adaptation. Biogerontology. 2016 Feb;17(1):147-57. doi: 10.1007/s10522-015-9615-7.

146. Bindu S, Dandapat S, Manikandan R, Dinesh M, Subbaiyan A, Mani P, Dhawan M, Tiwari R, Bilal M, Emran TB, Mitra S, Rabaan AA, Mutair AA, Alawi ZA, Alhumaid S, Dhama K. Prophylactic and therapeutic insights into trained immunity: A renewed concept of innate immune memory. Hum Vaccin Immunother. 2022 Mar 3:1-19. doi: 10.1080/21645515.2022.2040238. E

147. Ietto G, Mortara L, Dalla Gasperina D, Iovino D, Azzi L, Baj A, Ageno W, Genoni AP, Acquati F, Gallazzi M, Spina G, Coco G, Pierin F, Noonan D, Vigezzi A, Monti E, Iori V, Masci F, Franchi C, Di Saverio S, Carcano G. Immune-Mediated Mechanisms in Patients Testing Positive for SARS-CoV-2: Protocol for a Multianalysis Study. JMIR Res Protoc. 2022 Jan 25;11(1):e29892. doi: 10.2196/29892.

148. Edelman GM, Gally JA. Degeneracy and complexity in biological systems. Proceedings of the National Academy of Sciences, 2001; 98(24), 13763-13768.

149. Riley TP, Hellman LM, Gee MH, Mendoza JL, Alonso JA, Foley KC, Nishimura MI, Vander Kooi CW, Garcia KC, Baker BM. T cell receptor cross-reactivity expanded by dramatic peptide-MHC adaptability. Nat Chem Biol. 2018 Oct;14(10):934-942. doi: 10.1038/s41589-018-0130-4.

150. Petrova G, Ferrante A, Gorski J. Cross-reactivity of T cells and its role in the immune system. Crit Rev Immunol. 2012;32(4):349-72. doi: 10.1615/critrevimmunol.v32.i4.50.

151. Klein, SL, Flanagan KL. Sex differences in immune responses. Nature Reviews Immunology, 2016; 16(10), 626-638. doi: 10.1038/nri.2016.90.

152. Kriete A. Robustness and aging—a systems-level perspective. Biosystems, 2013; 112(1), 37-48. doi: 10.1016/j.biosystems.2013.03.014.

153. Johnson PL, Yates AJ, Goronzy JJ, Antia R. Peripheral selection rather than thymic involution explains sudden contraction in naive CD4 T-cell diversity with age. Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21432-7. doi: 10.1073/pnas.1209283110.

154. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018 Oct;14(10):576-590. doi: 10.1038/s41574-018-0059-4.

155. Xu W, Wong G, Hwang YY, Larbi A. The untwining of immunosenescence and aging. Semin Immunopathol. 2020 Oct;42(5):559-572. doi: 10.1007/s00281-020-00824-x.

156. Verschoor CP, Andrew MK, Loeb M, Pawelec G, Haynes L, Kuchel GA, McElhaney JE. Antibody and Cell-Mediated Immune Responses Are Correlates of Protection against Influenza Infection in Vaccinated Older Adults. Vaccines (Basel). 2021 Jan 7;9(1):25. doi: 10.3390/vaccines9010025.

157. Palacios-Pedrero MÁ, Osterhaus ADME, Becker T, Elbahesh H, Rimmelzwaan GF, Saletti G. Aging and Options to Halt Declining Immunity to Virus Infections. Front Immunol. 2021 May 12;12:681449. doi: 10.3389/fimmu.2021.681449.

158. Tanner AR, Dorey RB, Brendish NJ, Clark TW. Influenza vaccination: protecting the most vulnerable. Eur Respir Rev. 2021 Jan 13;30(159):200258. doi: 10.1183/16000617.0258-2020.

159. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2018 Feb 1;2(2):CD001269. doi: 10.1002/14651858.CD001269.pub6.

160. https://www.influenza.org.nz/

161. Dugan HL, Henry C, Wilson PC. Aging and influenza vaccine-induced immunity. Cell Immunol. 2020 Feb;348:103998. doi: 10.1016/j.cellimm.2019.103998.

162. Nguyen THO, Sant S, Bird NL, Grant EJ, Clemens EB, Koutsakos M, Valkenburg SA, Gras S, Lappas M, Jaworowski A, Crowe J, Loh L, Kedzierska K. Perturbed CD8(+) T cell immunity across universal influenza epitopes in the elderly. J Leukoc Biol. 2018 Feb;103(2):321-339. doi: 10.1189/jlb.5MA0517-207R.

163. Park HJ, Shin MS, Kim M, Bilsborrow JB, Mohanty S, Montgomery RR, Shaw AC, You S, Kang I. Transcriptomic analysis of human IL-7 receptor alpha (low) and (high) effector memory CD8(+) T cells reveals an age-associated signature linked to influenza vaccine response in older adults. Aging Cell. 2019 Aug;18(4):e12960. doi: 10.1111/acel.12960.

164. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006 Feb 20;24(8):1159-69. doi: 10.1016/j.vaccine.2005.08.105.

165. McElhaney JE, Verschoor CP, Andrew MK, Haynes L, Kuchel GA, Pawelec G.The immune response to influenza in older humans: beyond immune senescence. Immun Ageing. 2020 May 7;17:10. doi: 10.1186/s12979-020-00181-1.

166. Henry C, Zheng NY, Huang M, Cabanov A, Rojas KT, Kaur K, Andrews SF, Palm AE, Chen YQ, Li Y, Hoskova K, Utset HA, Vieira MC, Wrammert J, Ahmed R, Holden-Wiltse J, Topham DJ, Treanor JJ, Ertl HC, Schmader KE, Cobey S, Krammer F, Hensley

SE, Greenberg H, He XS, Wilson PC.   Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals. Cell Host Microbe. 2019 Mar 13;25(3):357-366.e6. doi: 10.1016/j.chom.2019.01.002.

167. Diaz Granados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, Martin E, Gurunathan S, Nathan R, Greenberg DP, Tornieporth NG, Decker MD, Talbot HK. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014 Aug 14;371(7):635-45. doi: 10.1056/NEJMoa1315727.

168. Lee JKH, Lam GKL, Shin T, Samson SI, Greenberg DP, Chit A. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis. Vaccine. 2021 Mar 15;39 Suppl 1:A24-A35. doi: 10.1016/j.vaccine.2020.09.004.

169. Tsai TF. Fluad-MF59-Adjuvanted Influenza Vaccine in Older Adults. Infect Chemother. 2013 Jun;45(2):159-74. doi: 10.3947/ic.2013.45.2.159.

170. Domnich A, Arata L, Amicizia D, Puig-Barberà J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine. 2017 Jan 23;35(4):513-520. doi: 10.1016/j.vaccine.2016.12.011.

171. Beran J, Reynales H, Poder A, Yu CY, Pitisuttithum P, Yuan LL, Vermeulen W, Verhoeven C, Leav B, Zhang B, Sawlwin D, Hamers-Heijnen E, Edelman J, Smolenov I. Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study. Lancet Infect Dis. 2021 Jul;21(7):1027-1037. doi: 10.1016/S1473-3099(20)30694-0.

172. Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clin Infect Dis. 2010 May 15;50(10):1331-8. doi: 10.1086/652144.

173. Merani S, Kuchel GA, Kleppinger A, McElhaney JE. Influenza vaccine-mediated protection in older adults: Impact of influenza infection, cytomegalovirus serostatus and vaccine dosage. Exp Gerontol. 2018 Jul 1;107:116-125. doi: 10.1016/j.exger.2017.09.015.

174. Ng TWY, Cowling BJ, Gao HZ, Thompson MG. Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-analysis. J Infect Dis. 2019 Apr 19;219(10):1525-1535. doi: 10.1093/infdis/jiy720.

175. Cowling BJ, Perera RAPM, Valkenburg SA, Leung NHL, Iuliano AD, Tam YH, Wong JHF, Fang VJ, Li APY, So HC, Ip DKM, Azziz-Baumgartner E, Fry AM, Levine MZ, Gangappa S, Sambhara S, Barr IG, Skowronski DM, Peiris JSM, Thompson MG. Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial. Clin Infect Dis. 2020 Oct 23;71(7):1704-1714. doi: 10.1093/cid/ciz1034.

176. Weinberger B. Adjuvant strategies to improve vaccination of the elderly population. Curr Opin Pharmacol. 2018 Aug;41:34-41. doi: 10.1016/j.coph.2018.03.014.

177. Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. PLoS One. 2017 Jan 6;12(1):e0169368. doi: 10.1371/journal.pone.0169368.

178. Diao WQ, Shen N, Yu P-X, Liu BB, He B. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials.   Vaccine. 2016 Mar 18;34(13):1496-1503. doi: 10.1016/j.vaccine.2016.02.023.

179. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD000422. doi: 10.1002/14651858.CD000422.pub3.

180. Wu YC, Kipling D, Dunn-Walters DK. Age-Related Changes in Human Peripheral Blood IGH Repertoire Following Vaccination. Front Immunol. 2012 Jul 9;3:193. doi: 10.3389/fimmu.2012.00193.

181. Berild JD, Winje BA, Vestrheim DF, Slotved HC, Valentiner-Branth P, Roth A, Storsäter J. A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population. Pathogens. 2020 Apr 3;9(4):259. doi: 10.3390/pathogens9040259.

182. Gessner BD, Jiang Q, Van Werkhoven CH, Sings HL, Webber C, Scott D, Gruber WC, Grobbee DE, Bonten MJM, Jodar L.A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands. Vaccine. 2019 Jul 9;37(30):4147-4154. doi: 10.1016/j.vaccine.2019.05.065.

183. Dion SB, Major M, Gabriela Grajales A, Nepal RM, Cane A, Gessner B, Vojicic J, Suaya JA. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines. Vaccine. 2021 May 21;39(22):3007-3017. doi: 10.1016/j.vaccine.2021.02.069.

184. McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, Carrico RM, Peyrani P, Wiemken TL, Mattingly WA, Ramirez JA, Jodar L. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clin Infect Dis. 2018 Oct 30;67(10):1498-1506. doi: 10.1093/cid/ciy312.

185. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE. Polysaccharide conjugate vaccine against pneumococcal pneumonia in   adults. N Engl J Med. 2015 Mar 19;372(12):1114-25. doi: 10.1056/NEJMoa1408544.

186. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009 Mar;9(3):213-20. doi: 10.1038/nri2494.

187. Lewnard JA, Bruxvoort KJ, Fischer H, Hong VX, Grant LR, Jódar L, Cané A, Gessner BD, Tartof SY. Effectiveness of 13-valent pneumococcal conjugate vaccine against medically-attended lower respiratory tract infection and pneumonia among older adults. Clin Infect Dis. 2021 Dec 30:ciab1051. doi: 10.1093/cid/ciab1051.

188. Cannon K, Elder C, Young M, Scott DA, Scully IL, Baugher G, Peng Y, Jansen KU, Gruber WC, Watson W. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination. Vaccine. 2021 Dec 17;39(51):7494-7502. doi: 10.1016/j.vaccine.2021.10.032.

189. Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, Sundaraiyer V, Peng Y, Moyer L, Pride MW, Scully IL, Jansen KU, Gruber WC, Scott DA, Watson W. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults 18 Years and Older. Clin Infect Dis. 2021 Dec 23:ciab990. doi: 10.1093/cid/ciab990.

190. Wyllie AL, Warren JL, Regev-Yochay G, Givon-Lavi N, Dagan R, Weinberger DM. Serotype Patterns of Pneumococcal Disease in Adults Are Correlated With Carriage Patterns in Older Children. Clin Infect Dis. 2021 Jun 1;72(11):e768-e775. doi: 10.1093/cid/ciaa1480.

191. Blom K, Yin L, Arnheim-Dahlström L. Effectiveness of the herpes zoster vaccine Zostavax® in Stockholm County, Sweden. Vaccine. 2019 Jul 18;37(31):4401-4406. doi: 10.1016/j.vaccine.2019.06.008.

192. Levin MJ, Weinberg A. Immune responses to zoster vaccines. Hum Vaccin Immunother. 2019;15(4):772-777. doi: 10.1080/21645515.2018.1560918.

193. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC; ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May 28;372(22):2087-96. doi: 10.1056/NEJMoa1501184.

194. Schwarz TF, Volpe S, Catteau G, Chlibek R, David MP, Richardus JH, Lal H, Oostvogels L, Pauksens K, Ravault S, Rombo L, Sonder G, Smetana J, Heineman T, Bastidas A. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother. 2018 Jun 3;14(6):1370-1377. doi: 10.1080/21645515.2018.1442162.

195. Weinberg A, Popmihajlov Z, Schmader KE, Johnson MJ, Caldas Y, Salazar AT, Canniff J, McCarson BJ, Martin J, Pang L, Levin MJ. Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine. J Infect Dis. 2019 Jan 7;219(2):335-338. doi: 10.1093/infdis/jiy514.

196. Heineman TC, Cunningham A, Levin M. Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. Curr Opin Immunol. 2019 Aug;59:42-48. doi: 10.1016/j.coi.2019.02.009.

197. Sullivan NL, Eberhardt CS, Wieland A, Vora KA, Pulendran B, Ahmed R. Understanding the immunology of the Zostavax shingles vaccine. Curr Opin Immunol. 2019 Aug;59:25-30. doi: 10.1016/j.coi.2019.02.005.

198. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389.

199. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577.

200. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Corbett KS, Swanson PA 2nd, Padilla M, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Martinez DR, Baric R, Buchanan W, Luke CJ, Phadke VK, Rostad CA, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study Group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020 Dec 17;383(25):2427-2438. doi: 10.1056/NEJMoa2028436.

201. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1.

202. Salvagno GL, Henry BM, di Piazza G, Pighi L, De Nitto S, Bragantini D, Gianfilippi GL, Lippi G. Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination. Diagnostics (Basel). 2021 May 4;11(5):832. doi: 10.3390/diagnostics11050832.

203. Lo Sasso B, Giglio RV, Vidali M, Scazzone C, Bivona G, Gambino CM, Ciaccio AM, Agnello L, Ciaccio M. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine. Diagnostics (Basel). 2021 Jun 22;11(7):1135. doi: 10.3390/diagnostics11071135.

204. Grupel D, Gazit S, Schreiber L, Nadler V, Wolf T, Lazar R, Supino-Rosin L, Perez G, Peretz A, Ben Tov A, Mizrahi-Reuveni M, Chodick G, Patalon T. Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination. Vaccine. 2021 Sep 7;39(38):5337-5340. doi: 10.1016/j.vaccine.2021.08.025.

205. Mwimanzi FM, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Datwani S, Omondi FH, Burns L, Young L, Leung V, Agafitei O, Ennis S, Dong W, Basra S, Lim LY, Ng K, Pantophlet R, Brumme CJ, Montaner JSG, Prystajecky N, Lowe CFJ, DeMarco M, Holmes DT, Simons J, Niikura M, Romney MG, Brumme ZL, Brockman MA. Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third Dose. medRxiv. 2022 Feb 21:2022.01.06.22268745. doi: 10.1101/2022.01.06.22268745.

206. Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, Wu Z, Jiang D, Deng X, Chu K, Zheng W, Wang L, Lu W, Han B, Zhao Y, Zhu F, Yu H, Yin W. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2021 Dec 7:S1473-3099(21)00681-2. doi: 10.1016/S1473-3099(21)00681-2.

207. Mudd PA, Remy KE. Prolonged adaptive immune activation in COVID-19: implications for maintenance of long-term immunity? J Clin Invest. 2021 Jan 4;131(1):e143928. doi: 10.1172/JCI143928.

208. Edwards DK, Jasny E, Yoon H, Horscroft N, Schanen B, Geter T, Fotin-Mleczek M, Petsch B, Wittman V. Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J Transl Med. 2017 Jan 3;15(1):1. doi: 10.1186/s12967-016-1111-6.

209. Linares-Fernández S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response. Trends Mol Med. 2020 Mar;26(3):311-323. doi: 10.1016/j.molmed.2019.10.002.

210. Salminen A. Activation of immunosuppressive network in the aging process. Ageing Res Rev. 2020 Jan;57:100998. doi: 10.1016/j.arr.2019.100998.

211. Churov AV, Mamashov KY, Novitskaia AV. Homeostasis and the functional roles of CD4(+) Treg cells in aging. Immunol Lett. 2020 Oct;226:83-89. doi: 10.1016/j.imlet.2020.07.004.

212. Salminen A. Increased immunosuppression impairs tissue homeostasis with aging and age-related diseases. J Mol Med (Berl). 2021 Jan;99(1):1-20. doi: 10.1007/s00109-020-01988-7.

213. Pawelec G, Picard E, Bueno V, Verschoor CP, Ostrand-Rosenberg S. MDSCs, ageing and inflammageing. Cell Immunol. 2021 Apr;362:104297. doi: 10.1016/j.cellimm.2021.104297.

214. Fulop T, Larbi A, Hirokawa K, Cohen AA, Witkowski JM. Immunosenescence is both functional/adaptive and dysfunctional/maladaptive. Semin Immunopathol. 2020 Oct;42(5):521-536. doi: 10.1007/s00281-020-00818-9.

215. Goronzy JJ, Weyand CM. Successful and Maladaptive T Cell Aging. Immunity. 2017 Mar 21;46(3):364-378. doi: 10.1016/j.immuni.2017.03.010.

216. Hussien H, Nastasa A, Apetrii M, Nistor I, Petrovic M, Covic A. Different aspects of frailty and COVID-19: points to consider in the current pandemic and future ones. BMC Geriatr. 2021 Jun 27;21(1):389. doi: 10.1186/s12877-021-02316-5.

217. Cohen AA. Complex systems dynamics in aging: new evidence, continuing questions. Biogerontology. 2016 Feb;17(1):205-20. doi: 10.1007/s10522-015-9584-x.

218. Mangel M.J. Complex adaptive systems, aging and longevity. Theor Biol. 2001 Dec 21;213(4):559-71. doi: 10.1006/jtbi.2001.2431.

219. Holden LM. Complex adaptive systems: concept analysis. J Adv Nurs. 2005 Dec;52(6):651-7. doi: 10.1111/j.1365-2648.2005.03638.x.

220. Li S, Nakaya HI, Kazmin DA, Oh JZ, Pulendran B. Systems biological approaches to measure and understand vaccine immunity in humans. Semin Immunol. 2013 Oct 31;25(3):209-18. doi: 10.1016/j.smim.2013.05.003.

221. Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity. 2010 Oct 29;33(4):516-29. doi: 10.1016/j.immuni.2010.10.006.

222. Cortese M, Sherman AC, Rouphael NG, Pulendran B. Systems Biological Analysis of Immune Response to Influenza Vaccination. Cold Spring Harb Perspect Med. 2021 Jun 1;11(6):a038596. doi: 10.1101/cshperspect.a038596.

223. Arunachalam PS, Scott MKD, Hagan T, Li C, Feng Y, Wimmers F, Grigoryan L, Trisal M, Edara VV, Lai L, Chang SE, Feng A, Dhingra S, Shah M, Lee AS, Chinthrajah S, Sindher SB, Mallajosyula V, Gao F, Sigal N, Kowli S, Gupta S, Pellegrini K, Tharp G, Maysel-Auslender S, Hamilton S, Aoued H, Hrusovsky K, Roskey M, Bosinger SE, Maecker HT, Boyd SD, Davis MM, Utz PJ, Suthar MS, Khatri P, Nadeau KC, Pulendran B. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature. 2021 Aug;596(7872):410-416. doi: 10.1038/s41586-021-03791-x.

224. Tomic A, Pollard AJ, Davis MM. Systems Immunology: Revealing Influenza Immunological Imprint. Viruses. 2021 May 20;13(5):948. doi: 10.3390/v13050948.

225. Zierer J, Menni C, Kastenmüller G, Spector TD. Integration of 'omics' data in aging research: from biomarkers to systems biology. Aging Cell. 2015 Dec;14(6):933-44. doi: 10.1111/acel.12386.

226. Rodrigues S, Desroches M, Krupa M, Cortes JM, Sejnowski TJ, Ali AB. Time-coded neurotransmitter release at excitatory and inhibitory synapses. Proceedings of the National Academy of Sciences. 2016 Feb 23;113(8):E1108-15.

227. Fülöp, T, Desroches, M, Cohen, AA, Santos, FAN and Rodrigues, S. Why we should use topological data analysis in ageing: towards defining the "topological shape of ageing". Mechanisms of Ageing and Development. 2020 192: 111390.

228. Bulut O, Kilic G, Domínguez-Andrés J, Netea MG. Overcoming immune dysfunction in the elderly: trained immunity as a novel approach. Int Immunol. 2020 Nov 23;32(12):741-753. doi: 10.1093/intimm/dxaa052.

229. Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020 Nov;288(5):518-536. doi: 10.1111/joim.13141.

230. De Maeyer RPH, van de Merwe RC, Louie R, Bracken OV, Devine OP, Goldstein DR, Uddin M, Akbar AN, Gilroy DW. Blocking elevated p38 MAPK restores efferocytosis and inflammatory resolution in the elderly. Nat Immunol. 2020 Jun;21(6):615-625. doi: 10.1038/s41590-020-0646-0.

231. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a Tool to Target Aging. Cell Metab. 2016 Jun 14;23(6):1060-1065. doi: 10.1016/j.cmet.2016.05.011.

232. Lanna A, Gomes DC, Muller-Durovic B, McDonnell T, Escors D, Gilroy DW, Lee JH, Karin M, Akbar AN. A sestrin-dependent Erk-Jnk-p38 MAPK activation complex inhibits immunity during aging. Nat Immunol. 2017 Mar;18(3):354-363. doi: 10.1038/ni.3665.

Table 1.

The past and present vaccines for older subjects considering their clinical efficiency

Vaccines	Younger individuals	Older individuals
Influenza		
Standard dose	+/-	-
High dose	+	++
Herpes Zoster		
Zostavax	NIL	+
Shingrix	NIL	++
SARS-CoV-2 (after 3rd dose)	+	+
Pneumococcus		
Polysaccharide	+/-	-
Conjugated	+	+
Yellow fever	+	+
Hepatitis B virus	+	+
Japanese encephalitis virus	+	+